This Insider Has Just Sold Shares In Aura Biosciences
This Insider Has Just Sold Shares In Aura Biosciences
Investors may wish to note that the Chief Technology Officer of Aura Biosciences, Inc., Mark Plavsic, recently netted US$73k from selling stock, receiving an average price of US$9.85. On the bright side, that's just a small sale and only reduced their holding by 5.7%.
投資者可能希望注意到Aura Biosciences, Inc.的首席技術官Mark Plavsic最近從出售股票中淨賺了7.3萬美元, 平均每股售價爲9.85美元。美好的一面是,那只是一個小額交易,僅減少了他們持有的5.7%。
The Last 12 Months Of Insider Transactions At Aura Biosciences
在Aura Biosciences的最近12個月的內部交易中,獨立董事會主席大衛·約翰遜進行了最大的內部購買。這次交易的金額是每股7.30美元的140萬美元股票。即使購買價格顯著低於最近的價格(9.02美元),我們仍認爲內部購買是積極的。因爲它發生在一個較低的估值上,這並不告訴我們內部人士是否認爲今天的價格具有吸引力。
The Independent Chairman of the Board David Johnson made the biggest insider purchase in the last 12 months. That single transaction was for US$1.4m worth of shares at a price of US$7.30 each. We do like to see buying, but this purchase was made at well below the current price of US$10.29. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
董事會獨立主席David Johnson在過去12個月中進行了最大規模的內部購買。那筆單一交易價值140萬美元,每股價格爲7.30美元。我們喜歡看到買入,但這次購買價格遠低於目前的10.29美元。雖然這表明內部人士認爲股票被低估了,但這筆交易並不能告訴我們他們對現在股價的看法。
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
下面的圖表顯示了過去一年內公司和個人的內部交易情況。如果您想確切地知道誰以多少價錢在何時賣出,請單擊下面的圖表!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
還有很多其他的公司,公司的內部人士正在購買股票。你可能不想錯過這個免費的小市值公司的低估列表。
Insider Ownership Of Aura Biosciences
Aura Biosciences 內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Aura Biosciences insiders own about US$6.0m worth of shares (which is 1.2% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
審視一家公司的總內部持股量可以幫助您判斷他們與普通股東是否高度一致。通常情況下,持股比例越高,內部人員就越有動力長期建設公司。我們的數據顯示,Aura Biosciences 內部人員持有價值約600萬美元的股份(佔公司的1.2%)。總的來說,這種持有比例並不令人印象深刻,但至少勝過沒任何。
So What Do The Aura Biosciences Insider Transactions Indicate?
那麼AURA生物科技的內部交易意味着什麼?
An insider hasn't bought Aura Biosciences stock in the last three months, but there was some selling. But we take heart from prior transactions. Still, insiders don't own a great deal of the stock. So overall it's hard to argue insiders are bullish. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 4 warning signs for Aura Biosciences you should be aware of, and 2 of these are a bit concerning.
最近三個月內沒有內部人員買入 Aura Biosciences 股票,但有賣出情況。但我們對之前的交易持樂觀態度。然而,內部人員並沒有持有大量股票。因此,整體而言,很難說內部人員看好。雖然了解內部人員持股和交易情況很重要,但在做出任何投資決策之前,我們還要考慮股票面臨的風險。一個例子是:我們發現 Aura Biosciences 存在4個警示信號,您需要注意其中的2個是有點令人擔憂的。
Of course Aura Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,Aura Biosciences可能不是最好的股票購買選擇。因此,您可能希望查看這個高質量公司的免費合集。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。